NLS Pharmaceutics AG is a biotechnology business based in the US. NLS Pharmaceutics shares (NLSP) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $2.46 |
|---|---|
| 52-week range | $2.06 - $4.70 |
| 50-day moving average | $2.56 |
| 200-day moving average | $2.99 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.46 from 2021-10-18
| 1 week (2021-10-12) | 2.50% |
|---|---|
| 1 month (2021-09-17) | -6.46% |
| 3 months (2021-07-19) | -18.00% |
| 6 months (2021-04-19) | -15.46% |
| 1 year (2020-10-15) | N/A |
|---|---|
| 2 years (2019-10-15) | N/A |
| 3 years (2018-10-15) | N/A |
| 5 years (2016-10-15) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -80.82% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $0.35 |
| Market capitalisation | $29.1 million |
TTM: trailing 12 months
There are currently 48,916 NLS Pharmaceutics shares held short by investors – that's known as NLS Pharmaceutics's "short interest". This figure is 55.2% down from 109,200 last month.
There are a few different ways that this level of interest in shorting NLS Pharmaceutics shares can be evaluated.
NLS Pharmaceutics's "short interest ratio" (SIR) is the quantity of NLS Pharmaceutics shares currently shorted divided by the average quantity of NLS Pharmaceutics shares traded daily (recently around 74115.151515152). NLS Pharmaceutics's SIR currently stands at 0.66. In other words for every 100,000 NLS Pharmaceutics shares traded daily on the market, roughly 660 shares are currently held short.
To gain some more context, you can compare NLS Pharmaceutics's short interest ratio against those of similar companies.
However NLS Pharmaceutics's short interest can also be evaluated against the total number of NLS Pharmaceutics shares, or, against the total number of tradable NLS Pharmaceutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NLS Pharmaceutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 NLS Pharmaceutics shares in existence, roughly 0 shares are currently held short) or 0.0104% of the tradable shares (for every 100,000 tradable NLS Pharmaceutics shares, roughly 10 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against NLS Pharmaceutics.
Find out more about how you can short NLS Pharmaceutics stock.
We're not expecting NLS Pharmaceutics to pay a dividend over the next 12 months.
You may also wish to consider:
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.